Prognosis of MDS patients An International Prognostic Scoring System (IPSS) is specially designed to access the prognosis of myelodysplastic syndrome patients. Scores help to classify patients into low, intermediate-1, intermediate-2 and high risks based on their severity levels. Patients in the lower-risk group generally have a longer survival range of 3-8.8 years, comparing to only 0.8-1.6 years for high-risk patients. In general, the survival rate of<unk>  patients is increasing. This is due to the improvements in transfusion procedures, mature use of iron chelation therapies to reduce iron overloading, and more experiences in dealing with associated morbidities.
Transfusion-dependent anemia
Post-transfusion purpura
Acute hemolytic transfusion reaction
Acquired hemolytic anemia
Delayed hemolytic transfusion reaction
Acute posthemorrhagic anemia
Mixed autoimmune hemolytic anemia
Mechanical hemolytic anemia